Macquarie Group’s ChemoCentryx, Inc. CCXI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-430
| Closed | -$77K | – | 2245 |
|
|
2022
Q3 | $77K | Sell |
430
-364
| -46% | -$15K | ﹤0.01% | 1839 |
|
|
2022
Q2 | $20K | Hold |
794
| – | – | ﹤0.01% | 2319 |
|
|
2022
Q1 | $20K | Hold |
794
| – | – | ﹤0.01% | 2398 |
|
|
2021
Q4 | $29K | Sell |
794
-563
| -41% | -$19.8K | ﹤0.01% | 2316 |
|
|
2021
Q3 | $23K | Hold |
1,357
| – | – | ﹤0.01% | 2433 |
|
|
2021
Q2 | $18K | Sell |
1,357
-1,282,351
| -100% | -$31.6M | ﹤0.01% | 2386 |
|
|
2021
Q1 | $65.8M | Buy |
1,283,708
+265,553
| +26% | +$16M | 0.09% | 267 |
|
|
2020
Q4 | $63M | Buy |
1,018,155
+158,063
| +18% | +$9.05M | 0.09% | 258 |
|
|
2020
Q3 | $47.1M | Buy |
860,092
+376,054
| +78% | +$20.2M | 0.08% | 282 |
|
|
2020
Q2 | $27.9M | Buy |
484,038
+97,962
| +25% | +$5.33M | 0.05% | 395 |
|
|
2020
Q1 | $15.5M | Buy |
+386,076
| New | +$16.4M | 0.03% | 469 |
|
|
2019
Q1 | – | Sell |
-3,800
| Closed | -$41K | – | 2162 |
|
|
2018
Q4 | $41K | Sell |
3,800
-900
| -19% | -$9.49K | ﹤0.01% | 1635 |
|
|
2018
Q3 | $59K | Sell |
4,700
-5,200
| -53% | -$62.7K | ﹤0.01% | 1697 |
|
|
2018
Q2 | $130K | Buy |
+9,900
| New | +$118K | ﹤0.01% | 1779 |
|
|
2018
Q1 | – | Sell |
-1,500
| Closed | -$9K | – | 2443 |
|
|
2017
Q4 | $9K | Sell |
1,500
-7,131
| -83% | -$48.9K | ﹤0.01% | 2290 |
|
|
2017
Q3 | $64K | Buy |
+8,631
| New | +$71.8K | ﹤0.01% | 1981 |
|
Other funds holding CCXI
Macquarie Group's CCXI Position: Q4 2022 in Review
Macquarie Group sold out of ChemoCentryx, Inc. (CCXI) in Q4 2022, closing a stake of 430 shares — an estimated $77K sold.
Macquarie Group first reported a position in CCXI in Q3 2017 and held it in 16 quarters. The position peaked at $65.8M in Q1 2021. 1 fund tracked by Wall St. Rank holds CCXI as of Q4 2022.
- Macquarie Group reported no remaining ChemoCentryx, Inc. position as of Q4 2022 after selling out during the quarter.
- Macquarie Group sold 430 ChemoCentryx, Inc. shares in Q4 2022, an estimated $77K.
- Macquarie Group first reported a position in ChemoCentryx, Inc. in Q3 2017 and held it in 16 quarters.
- Macquarie Group's ChemoCentryx, Inc. position peaked at $65.8M in Q1 2021.
- 1 fund tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2022.
Based on Macquarie Group's 13F filing for Q4 2022, filed 21 Feb 2023.